Patents by Inventor Arnout Gerritsen
Arnout Gerritsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11548950Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful correcting a deficient level progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).Type: GrantFiled: November 13, 2020Date of Patent: January 10, 2023Assignee: H. Lundbeck A/SInventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
-
Publication number: 20210292414Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).Type: ApplicationFiled: December 11, 2020Publication date: September 23, 2021Applicant: H. Lundbeck A/SInventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren, Esben Trabjerg, Kasper Dyrberg Rand
-
Publication number: 20210269524Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful correcting a deficient level progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).Type: ApplicationFiled: November 13, 2020Publication date: September 2, 2021Applicant: H. Lundbeck A/SInventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
-
Publication number: 20210269509Abstract: The present invention relates to a method for controlling the composition of a mixture of two or more different antibodies, such as tow or more different monoclonal antibodies, using chromatography. The mixture is for use as a drug product and the method includes a controlled downstream process for the production of a predetermined ratio of the two or more different antibodies.Type: ApplicationFiled: June 24, 2019Publication date: September 2, 2021Inventors: Richard HIBBERT, Rob DE JONG, Aran Frank LABRIJN, Arnout GERRITSEN, Janine SCHUURMAN, Paul PARREN
-
Patent number: 10894833Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).Type: GrantFiled: July 17, 2018Date of Patent: January 19, 2021Assignee: H. Lundbeck A/SInventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren
-
Patent number: 10889650Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).Type: GrantFiled: July 24, 2019Date of Patent: January 12, 2021Assignee: H. Lundbeck A/SInventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
-
Publication number: 20200190188Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).Type: ApplicationFiled: July 24, 2019Publication date: June 18, 2020Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
-
Patent number: 10479835Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).Type: GrantFiled: July 12, 2016Date of Patent: November 19, 2019Assignee: H. Lundbeck A/SInventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward Van Den Brink, Paul Parren, Rob De Jong
-
Patent number: 10428147Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).Type: GrantFiled: July 12, 2016Date of Patent: October 1, 2019Assignee: H. Lundbeck A/SInventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Søren Christensen, Jan Egebjerg, Jeffrey B. Stavenhagen, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
-
Patent number: 10344050Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.Type: GrantFiled: October 26, 2012Date of Patent: July 9, 2019Assignee: GENMAB A/SInventors: Michael Gramer, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kampen, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Arnout Gerritsen
-
Publication number: 20190023788Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).Type: ApplicationFiled: July 17, 2018Publication date: January 24, 2019Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren
-
Publication number: 20180305455Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).Type: ApplicationFiled: July 12, 2016Publication date: October 25, 2018Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey b. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward Van Den Brink, Paul Parren, Rob De Jong
-
Publication number: 20170267761Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).Type: ApplicationFiled: July 12, 2016Publication date: September 21, 2017Applicant: H. Lundbeck A/SInventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Søren Christensen, Jan Egebjerg, Jeffrey B. Stavenhagen, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
-
Publication number: 20140303356Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.Type: ApplicationFiled: October 26, 2012Publication date: October 9, 2014Applicants: GENMAB A/SInventors: Michael Gramer, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kamper, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Arnout Gerritsen
-
Publication number: 20070253958Abstract: The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to CD32 with high affinity and have particular functional properties, such as inhibiting ligand binding, down-modulating surface expression of CD32 or specifically binding to the Fc?RIIa-H131 allotype but not the Fc?RIIa-R131 allotype. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules, vaccine conjugates and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting CD32, in particular for detecting the Fc?RIIa-H131 allotype, methods of treatment using the antibodies of the invention, such as methods for treating autoimmune hemolytic anemia, and methods for enhancing antigen presentation using the antibodies of the invention.Type: ApplicationFiled: March 30, 2007Publication date: November 1, 2007Applicant: MEDAREX, INC.Inventors: Jan Van De Winkel, Marcus Van Dijk, Arnout Gerritsen